

1 **The efficacy and safety of monoclonal antibody treatments against COVID-19: A
2 systematic review and meta-analysis of randomized clinical trials**

3

4 Ifan Ali Wafa^a, Nando Reza Pratama^a, David Setyo Budi^a, Henry Sutanto^{b,c}, Alfian Nur
5 Rosyid^d, Citrawati Dyah Kencono Wungu^{e,f,*}

6

7

8

9 ^aFaculty of Medicine, Universitas Airlangga, Indonesia

10 ^bDepartment of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht
11 University, The Netherlands

12 ^cDepartment of Physiology and Biophysics, State University of New York (SUNY)
13 Downstate Health Sciences University, New York, USA

14 ^dDepartment of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas
15 Airlangga, Indonesia

16 ^eDepartment of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas
17 Airlangga, Indonesia

18 ^fInstitute of Tropical Disease, Universitas Airlangga, Indonesia

19

20

21

22

23

24 **Word Count:** 3480 words (excluding abstract and references)

25

26

27

28

29 **Correspondence:**

30 Citrawati Dyah Kencono Wungu, MD., PhD.

31 Department of Physiology and Medical Biochemistry, Airlangga University

32 Jalan Mayjen Prof. Dr. Moestopo No.47, Surabaya, Indonesia

33 Email: citrawati.dyah@fk.unair.ac.id

34

35 **Abstract**

36 **Objectives:** The use of monoclonal antibody for COVID-19 showed conflicting results in
37 prior studies and its efficacy remains unclear. We aimed to comprehensively
38 determine the efficacy and safety profile of monoclonal antibodies in COVID-
39 19 patients.

40 **Methods:** Sixteen RCTs were analyzed using RevMan 5.4 to measure the pooled
41 estimates of risk ratios (RRs) and standardized mean differences (SMDs) with
42 95% CIs.

43 **Results:** The pooled effect of monoclonal antibodies demonstrated mortality risk
44 reduction (RR=0.89 (95%CI 0.82-0.96), $I^2=13\%$, fixed-effect). Individually,
45 tocilizumab reduced mortality risk in severe to critical disease (RR=0.90
46 (95%CI 0.83-0.97), $I^2=12\%$, fixed-effect)) and lowered mechanical ventilation
47 requirements (RR=0.76 (95%CI 0.62-0.94), $I^2=42\%$, random-effects). Moreover,
48 it facilitated hospital discharge (RR=1.07 (95%CI 1.00-1.14),
49 $I^2=60\%$, random-effects). Meanwhile, bamlanivimab-etesevimab and REGN-
50 COV2 decrease viral load ((SMD=-0.33 (95%CI -0.59 to
51 -0.08); (SMD=-3.39 (95%CI -3.82 to -2.97)). Interestingly, monoclonal
52 antibodies did not improve hospital discharge at day 28-30 (RR=1.05 (95%CI
53 0.99–1.12), $I^2=71\%$, random-effects) and they displayed similar safety profile
54 with placebo/standard therapy (RR=1.04 (95%CI 0.76-1.43), $I^2=54\%$, random-
55 effects).

56 **Conclusion:** Tocilizumab improved hospital discharge and reduced mortality as well as the
57 need for mechanical ventilation, while bamlanivimab-etesevimab and REGN-
58 COV2 reduced viral load in mild to moderate outpatients. In general,
59 monoclonal antibodies are safe and should be considered in severe to critical
60 COVID-19 patients.

61 **Keywords:** COVID-19; Monoclonal Antibody; Mortality; Viral load; Meta-analysis

62 **Registration:** PROSPERO (CRD42021235112)

63 INTRODUCTION

64 Since December 2019, a novel coronavirus disease (COVID-19) firstly discovered in
65 Wuhan, China has spread globally and profoundly affected various aspects of life (Li et al.,
66 2020). The viral infectious disease is caused by SARS-CoV-2; an enveloped, positive-sense,
67 single-stranded genomic ribonucleic acid (+ssRNA) virus from the group of *Betacoronavirus*
68 in the family of *Coronaviridae* (Hu et al., 2021). In the lungs, SARS-CoV-2 binds to
69 angiotensin converting enzyme type-2 (ACE-2) receptors at the membrane of pulmonary
70 alveolar cells type-2 and undergoes endocytosis. Subsequently, the interaction of viral
71 antigen with RIG-I-like receptors (RLRs) activates the host immune system as an effort to
72 eliminate the virus from the body (Hertanto et al., 2021), predisposing to the clinical
73 presentations of COVID-19 patients, ranging from asymptomatic or mild up to severe disease
74 state with pneumonia and acute respiratory distress syndrome that can ultimately lead to
75 death (Lai et al., 2020).

76 The development of optimal and effective therapies for COVID-19 is essential to
77 minimize COVID-19 morbidity and mortality (Lu, 2020; Li and De Clercq, 2020). Several
78 components of the virus and host immune system have been identified as potential targets in
79 COVID-19 management. A previous study reported that the SARS-CoV-2 S2 protein was
80 important for viral entry and thought to be a potential target for neutralizing antibody (Walls
81 et al., 2020). Moreover, the SARS-CoV-2 infection could trigger a hyperactive immune
82 response, leading to cytokine release syndrome (CRS) or cytokine storm (Hertanto et al.,
83 2021). Among numerous proinflammatory cytokines involved in CRS, interleukin (IL)-6 is
84 one of the most critical and has been associated with a poor prognosis (Zhang et al., 2020a;
85 Zhang et al., 2020b; Zhao, 2020). Therefore, the inhibition of IL-6 (e.g., by preventing the
86 binding to its receptors) could prevent the occurrence of CRS and lower the severity of the
87 disease. Moreover, complement C5a and white blood cells (i.e., neutrophil and monocytes)
88 were detected in the bronchoalveolar lavage fluid (BALF) of COVID-19 patients, supporting
89 the chemoattraction role of C5a in lungs-derived C5aR1-expressing cells; which is
90 responsible for cell damage and ARDS (Carvelli et al., 2020). Of note, C5a is one of the
91 major drivers for complement-mediated inflammation that rapidly responds to pathogens and
92 cellular injury (Woodruff and Shukla, 2020).

93 Monoclonal antibody is one of the proposed therapeutic options for COVID-19. Anti-
94 SARS-CoV-2 monoclonal antibodies are among the latest investigational COVID-19
95 treatments granted with emergency use authorization (EUA) from the United States Food and

96 Drug Administration (FDA). Briefly, monoclonal antibodies recognize one epitope of an
97 antigen while polyclonal antibodies recognize multiple epitopes (Lipman et al., 2005). The
98 variable region can be modified to target specific molecules, including the S2-protein,
99 cytokines, and cytokine receptors. Among 5 Antibody isotypes—IgA (subclasses IgA1 and
100 IgA2), IgE, IgD, IgM, and IgG (subclasses IgG1, IgG2, IgG3 and IgG4)—IgG is commonly
101 selected for therapeutic purposes due to its strong binding affinity to an antigen and its Fc
102 receptor, supported by its long serum half-life (Chames et al., 2009; Lu, 2020). As the
103 consequence, the administration of neutralizing monoclonal antibody targeting SARS-CoV-2
104 spike proteins allows the inhibition of virus attachment to human ACE-2 receptors, thus
105 inhibits viral entry (Tian et al., 2020). To prevent complement system activation triggered
106 during SARS-CoV-2 infection, a recent study proposed the use of monoclonal antibody
107 against C5a (anti-C5a) (Woodruff and Shukla, 2020). Among available monoclonal
108 antibodies for COVID-19, anti-IL-6 receptors and anti-SARS-CoV-2 are widely studied in
109 clinical trials (Yang et al., 2020; Patel et al., 2021).

110 Nonetheless, the efficacy and safety of this pharmacological agent remain
111 controversial (FDA, 2020; Patel et al., 2021). Moreover, at present, the application of
112 monoclonal antibody as a therapeutic agent in COVID-19 shows conflicting results in prior
113 studies, demanding further investigations. Thus, this meta-analysis aims to assess the
114 previously reported efficacy and safety of monoclonal antibodies on clinical and laboratory
115 outcomes and its safety profile in COVID-19 patients.

116

117 MATERIALS AND METHODS

118 Search Strategy

119 The PubMed (MEDLINE), ScienceDirect, Cochrane Library, Proquest and Springer
120 databases were systematically searched from January 25 until February 5, 2021, without any
121 limitation of publication year. We also performed manual searches, extended from February 5
122 to March 5, 2021, through MedRxiv and citation searching to get evidence from unpublished
123 data and retrieve potential articles without missing any additional eligible studies. The
124 following keywords were used: “(COVID-19) AND ((Monoclonal Antibody) OR
125 (Neutralizing Antibody) OR (Serotherapy)) AND ((Viral Load) OR (Oxygen) OR (Duration)
126 OR (Mortality) OR (Inflammation))”. Additional details about the search strategy are
127 available in *Supplementary Materials*.

128 **Data Collection**

129 The title and abstract of the articles were screened by IAW and NRP. Duplications
130 were removed using the Mendeley reference manager. We independently screened the title
131 and abstract of all retrieved studies based on the following eligibility criteria: (1) participants
132 confirmed at any clinical stage of COVID-19 with/without other comorbidities; (2) adult (≥ 18
133 years) male/female study population; (3) the study involved monoclonal antibody treatments
134 of interest; (4) the study compared the intervention group with control (placebo or/and
135 standard of care or combination therapy); (5) the study evaluated efficacy (i.e. mortality, need
136 for mechanical ventilation, hospital discharge, virologic outcomes) or safety outcomes
137 (serious adverse events); (6) study type was randomized controlled trial (RCT).

138 **Data Extraction and Quality Assessment**

139 IAW, NRP, and DSB independently extracted relevant data using the standardized
140 form. The following information was extracted: first author's name and publication year,
141 study design, country, sample size, age, disease severity, dosage and administration of
142 monoclonal antibodies, types of comparison, and outcomes (all-cause mortality, need for
143 mechanical ventilation, hospital discharge at day 28-30, change of viral load, and serious
144 adverse events). Serious adverse events were defined as any untoward medical occurrence
145 that are potentially related to monoclonal antibody treatment.

146 The studies were classified into "low risk of bias," "some concerns," or "high risk of
147 bias" according to the Cochrane risk of bias tool for randomized trial (RoB ver.2) (Sterne et
148 al., 2019). Any discrepancies were consulted with an expert and resolved by discussion until
149 reaching consensus. The Grading of Recommendation Assessment, Development, and
150 Evaluation (GRADE) system was used to evaluate the quality of evidence of the findings
151 (Brignardello-Petersen et al., 2018; Puhan et al., 2014).

152 **Statistical Analysis**

153 Primary analyses were carried out using the Review Manager version 5.4 (The
154 Cochrane Collaboration). Pooled risk ratios (RRs) for dichotomous outcomes were evaluated
155 using Mantel-Haenszel method. Standardized mean differences (SMDs) of continuous
156 outcomes were pooled using inverse variance. I^2 test was used to quantify heterogeneity
157 between studies, with values $I^2 > 50\%$ represents moderate-to-high heterogeneity. If the value
158 of I^2 statistics was $< 50\%$ or the p -value was > 0.1 , the fixed-effects model could be applied;
159 otherwise, the random-effects model would be used. Begg's funnel plot and Egger's test were

160 performed for publication bias analysis, and if present, trim-and-fill method was performed.
161 All statistical analysis with a p -value <0.05 was considered statistically significant.

162 Subgroup analyses were done on monoclonal antibody types and disease severity for
163 mortality risk, and monoclonal antibody types for the other outcomes. Leave-one-out
164 sensitivity analysis was conducted to find the source of statistical heterogeneity and
165 demonstrate how each study affected the overall result. Fixed-effects and random-effects with
166 different tau estimators (DL, SJ, and HKSJ) were performed for sensitivity analysis using R
167 version 4.0.5 to find the robustness of pooled data (see *Supplementary Materials*).

168

169 RESULTS

170 Study characteristics

171 We identified 6032 and 7310 studies through primary database and manual searching,
172 respectively. After duplication removal, we screened potentially relevant studies and obtained
173 228 studies to be checked for eligibility. Some studies were excluded due to the reasons
174 documented in PRISMA diagram (*Figure 1*).

175 Among 16 RCTs, the REMAP-CAP trial (Gordon et al., 2021) was split into two
176 separate intervention groups: the tocilizumab and sarilumab groups. In total, there were 8857
177 participants included in the meta-analysis, consisted of 4700 and 4157 participants in the
178 intervention and control groups, respectively. The characteristics and outcomes summary for
179 each study, RoB ver.2 assessment, and the certainty of evidence of findings reported using
180 GRADE system are presented in *Supplementary Tables*.

181 MORTALITY

182 All-cause mortality

183 All-cause mortality was examined from 16 RCTs with a total of 8857 patients. Monoclonal
184 antibody was associated with a lower mortality risk (RR=0.89 (95%CI 0.82-0.96), $I^2=3\%$,
185 fixed-effects). Subsequently, subgroup analyses on the disease severity and monoclonal
186 antibody types were conducted, however only tocilizumab and sarilumab therapies for
187 severe-critical COVID-19 patients were pooled, due to limited studies available (*Figure 2*).

188 Tocilizumab in severe-critical COVID-19

189 Patients with severe-critical COVID-19 receiving tocilizumab displayed a lower mortality
190 risk (RR=0.90 (95%CI 0.83-0.97), $I^2=12\%$, fixed-effect). RECOVERY trial contributed to

191 the most weight in this meta-analysis (71.1%), and 82.3% in tocilizumab arm and 82.2% in
192 standard therapy arm receiving corticosteroid (pooled RR=0.87 (95%CI 0.80-0.95), $I^2=14\%$,
193 fixed-effects). Omitting this trial did not change the direction of effect, although it impaired
194 the statistical significance (RR=0.92 (95%CI 0.78-1.10), $I^2=25\%$, fixed-effects). Meanwhile,
195 TOCIBRAS trial mainly contributed to the statistical heterogeneity. Excluding this study
196 from the analysis provided a more consistent result (pooled RR=0.89 (95%CI 0.82-0.96),
197 $I^2=0\%$). At last, Funnel plot and Egger's test did not show any publication bias.

198 **Sarilumab in severe-critical COVID-19**

199 In severe to critical COVID-19 patients treated with sarilumab, the pooled effect was
200 evaluated using two studies: EudraCT and REMAP-CAP trials (RR=0.74 (95%CI 0.48-1.14),
201 $I^2=2\%$, fixed-effect). Numerically, the RR was lower than that of tocilizumab, but it did not
202 reach statistical significance. Egger's test cannot be performed because there were only two
203 studies included in the analysis.

204 **THE NEED FOR MECHANICAL VENTILATION**

205 Ten RCTs consisted of 6061 patients were examined (*Figure 3*). Only studies involving anti-
206 IL-6R antibodies reported mechanical ventilation outcome. All participants were in severe-
207 critical disease, except for the participants from COVINTOC trial who were in moderate-
208 severe state. Although IL-6R did not demonstrate a reduction of mechanical ventilation
209 requirements (RR=0.76 (95%CI 0.61-0.96, $I^2=49\%$, random-effects), subgroup analyses
210 revealed that tocilizumab significantly reduced the need for mechanical ventilation (RR=0.76
211 (95%CI 0.62-0.94), $I^2=42\%$, random-effects), but not sarilumab (RR=0.76 (95%CI 0.21-
212 2.78), $I^2=87\%$, random-effects). We also found that EMPACTA trial was the source of
213 heterogeneity in the tocilizumab subgroup. However, omitting this study yielded a similar
214 result (RR=0.81 (95%CI 0.72-0.91), $I^2=0\%$, fixed-effects). No publication bias was detected
215 from the funnel plot and Egger's test.

216 **HOSPITAL DISCHARGE AT DAY 28-30**

217 Eleven RCTs consisted of 7490 patients were examined (*Figure 4*). The overall effect of the
218 interventions on hospital discharge at day 28-30 showed no significant difference (RR=1.05
219 (95%CI 0.99-1.22), $I^2=71\%$, random-effects). Patients in tocilizumab and sarilumab
220 subgroups had severe-critical disease, while patients receiving spike-protein antibodies were
221 in moderate-severe COVID-19. Subsequently, subgroup analyses for sarilumab and
222 tocilizumab were performed and only tocilizumab significantly increased the rate of hospital

223 discharge (RR=1.07 (95%CI 1.00-1.14), $I^2=60\%$, random-effects). The p -value in 4
224 significant figures was 0.0498, therefore it reached statistical significance. The funnel plot
225 and Egger's test did not indicate any publication bias.

226 **CHANGE OF VIRAL LOAD**

227 Two RCTs consisted of 896 patients with bamlanivimab monotherapy (**Figure 5**) indicated
228 that bamlanivimab alone did not reduce viral load at day 11 (SMD=-0.07 (95%CI -0.21 to
229 0.07), $I^2=44\%$, fixed-effect), in contrast to the combination of bamlanivimab and etesevimab
230 (SMD=-0.33 (95%CI -0.59 to -0.08)). In addition, REGN-CoV2 significantly reduced viral
231 load at day 7 (SMD=-3.39 (95%CI -3.82 to -2.97)). However, only two studies included into
232 the analysis, thus Egger's test could not be performed.

233 **SERIOUS ADVERSE EVENTS**

234 In 16 RCTs of 8897 patients, the overall safety of monoclonal antibody did not differ from
235 placebo/standard therapy (RR=1.04 (95%CI 0.76-1.43), $I^2=54\%$, random-effects) (**Figure 6**),
236 as well as the subgroup analyses performed for anti-spike-protein (RR=1.00 (95%CI 0.67-
237 1.49) $I^2=29\%$, fixed-effect), tocilizumab (RR=0.96 (95%CI 0.79-1.18), $I^2=72\%$, random-
238 effects) and sarilumab (RR=1.12 (95%CI 0.74-1.70), $I^2=0\%$, fixed-effect). Interestingly, the
239 CORIMUNO-TOCI 1 trial reported that tocilizumab was significantly safer than
240 placebo/standard therapy. On the contrary, the EMPACTA trial showed that tocilizumab was
241 more harmful than placebo/standard therapy. These two studies were the main sources of
242 heterogeneity in our analysis, although removing those studies from the tocilizumab subgroup
243 did not change the direction of effect and statistical significance (RR=1.00 (95%CI 0.80-
244 1.24), $I^2=0\%$, fixed-effects). Publication bias was indicated in the anti-spike-protein
245 subgroup. The trim-and-fill method altered neither the direction of effect nor the statistical
246 significance (RR=0.92 (95%CI 0.63-1.36), $I^2=27\%$, fixed-effects).

247

248 **DISCUSSION**

249 Our analyses showed that monoclonal antibodies provided benefits on mortality rate
250 reduction, mostly because of the weight of tocilizumab studies. From subgroup analysis,
251 tocilizumab showed this benefit, while sarilumab did not. Analysis of the need for
252 mechanical ventilation was conducted by employing only anti-IL-6R studies since the others
253 did not report this outcome. Additionally, some RCTs were outpatients and in mild-moderate
254 disease. No significant benefit was found on hospital discharge at day 28-30 from pooling all

255 monoclonal antibodies. However, subgroup analysis demonstrated that tocilizumab had a
256 significantly higher hospital discharge rate, but sarilumab and bamlanivimab did not. Most of
257 the publications included in this study did not specify any specific description about the
258 hospital discharge. We obtained this data from the description of their ordinal severity scale.
259 In addition, the symptom progression score was not compared because it was described
260 differently across studies.

261 Next, we also performed a meta-analysis assessing the efficacy of monoclonal
262 antibodies in lowering viral load. For this particular purpose, all included studies employed
263 anti spike-proteins (Chen et al., 2021; Gottlieb et al., 2021; Weinreich et al., 2021). There
264 were three studied interventions—bamlanivimab, bamlanivimab-etesevimab, and REGN-
265 COV2. As the results, the pooled effect of bamlanivimab studies did not show significant
266 viral load reduction. Meanwhile, bamlanivimab-etesevimab and REGN-COV2 reported
267 significant viral load reduction, but each was evaluated only from one RCT, therefore we
268 cannot evaluate the pooled effect. Finally, safety profile should be taken into consideration
269 when administering monoclonal antibodies in COVID-19 patients. Our analyses showed that
270 monoclonal antibodies did not show significant harm or benefit as compared to
271 placebo/standard care. However, not all studies included in this meta-analysis specified the
272 number of treatment-related severe adverse events. The researchers considerably assumed
273 that severe adverse events were related to the treatment unless it was specified otherwise.

274 We believe that pooling different monoclonal antibodies into one outcome analysis is
275 not insightful since different interventions should be treated independently as they could
276 display varying results. Therefore, we also aimed to look into the subgroup analysis in
277 addition to the overall effect of the pooled antibodies.

278 **ANTI-IL-6R**

279 The efficacy of tocilizumab was mostly reported in studies where the participants received
280 corticosteroids, for example in RECOVERY and REMAP-CAP trials. If these studies were
281 excluded from the analysis, the pooled effect of mortality risk reduction was no longer
282 significant. This highlights the potential benefit of the combination of tocilizumab and
283 corticosteroids in mortality risk reduction. Indeed, it was shown that dexamethasone
284 significantly reduced mortality risk (Sterne et al, 2020). This could also indicate that the
285 tocilizumab effect may be additional to the corticosteroid benefit (Horby et al, 2021).
286 Whether the administration of tocilizumab alone, without another immunomodulatory agent,

287 would reduce mortality risk remains unclear. Therefore, it is recommended that the use of
288 tocilizumab in severe-critical COVID-19 patients is combined with corticosteroids rather than
289 tocilizumab alone.

290 Next, our subgroup analysis showed that tocilizumab was beneficial in reducing mechanical
291 ventilation needs and hospital discharge. Consistently, the benefits of tocilizumab in
292 improving oxygen-support and mechanical ventilation rate have been previously documented
293 (Aziz et al., 2021; Kotak et al., 2020; Tleyjeh et al., 2021). Additionally, REMAP-CAP and
294 EMPACTA trials reported that the administration of tocilizumab was associated with earlier
295 hospital discharge and reduction of hospital stay, respectively.

296 We failed to demonstrate the benefit of sarilumab in reducing the need for mechanical
297 ventilation and hospital discharge rate. This was in line with another study (Della-Torre et al.,
298 2020). The following are some of the proposed arguments to explain this finding. First, the
299 open-label REMAP-CAP trial showed that the sample size included in the sarilumab group
300 was smaller than the control group. Second, the double-blind EudraCT trial reported that
301 more than 60% of patients in the trial received systemic corticosteroids before, during, or
302 after infusion of the studied drug and the frequency of systemic corticosteroid varied during
303 the study. Consequently, it might have diminished the differences between the investigational
304 drug and the control group.

305 Anti IL-6R was generally safe and tolerable for the treatment of COVID-19 patients. A
306 previous study reported no significant differences between tocilizumab and control groups in
307 terms of the risk of treatment-related serious adverse events (Lin et al, 2021). Tocilizumab,
308 moreover, had a lower rate of serious infections compared to those in the control group
309 (Kotak et al, 2020; Lan et al., 2020; Zhao et al., 2021).

310 Lastly, the SARS-CoV-2 infection may result in excessive release of pro-inflammatory
311 cytokines, including IL-6, an important cytokine associated with disease severity and
312 mortality, which leads to hyperactivation of the immune response associated with acute
313 respiratory distress syndrome (Xu et al., 2020). However, although IL-6 is one of major
314 cytokines that drive CRS, IL-6 suppression alone might be insufficient to cease the
315 hyperinflammatory phase of COVID-19. Moreover, although there was an increased IL-6
316 level in COVID-19 patients, it was not as high as observed in sepsis or ARDS (Leisman et
317 al., 2020; Sinha et al., 2020). In general, healthcare providers need to consider patients with
318 severe COVID-19 to attain the maximum benefit from the inhibition of IL-6.

319 **ANTI-SPIKE-PROTEIN**

320 Viral load reduction of bamlanivimab was evaluated by two studies (Chen et al., 2021;
321 Gottlieb et al., 2021) from the same RCT, BLAZE-1 (NCT04427501). Both studies reported
322 that bamlanivimab 700mg and bamlanivimab 7000mg did not reduce viral load at day 11.
323 Gottlieb et al. (2021) reported that only bamlanivimab 2800mg showed a higher viral load
324 reduction although it was statistically insignificant, while Chen et al. (2020) reported that
325 bamlanivimab 2800mg significantly reduced viral load.

326 Prozone-like effect possibly plays a role for the reduced efficacy at higher dose, more likely
327 in the earlier time of the disease (Vaidya et al., 2017; Casadevall et al., 2021). Besides, the
328 natural course of the disease also plays a role in viral load reduction. This may mask the
329 clinical significance of neutralizing antibody administration. It is important to mention that
330 missing data from Gottlieb et al. (2020) was replaced using an approach detailed in
331 *Supplementary Materials*.

332 Among these anti-spike-protein antibodies, REGN-COV2 and bamlanivimab-etesevimab
333 showed statistically significant viral load reduction but bamlanivimab alone did not reduce
334 viral load. This finding was in line with FDA's decision published on 16 April 2021 stating
335 that FDA revoked its previously issued EUA for monoclonal antibody bamlanivimab (FDA,
336 2021). There is a possibility that etesevimab has superior efficacy on viral load reduction.
337 Another possibility is that etesevimab and bamlanivimab may have synergistic effects.
338 However, further research on clinical efficacy of etesevimab monotherapy and its
339 pharmacokinetics with bamlanivimab are warranted.

340 Finally, it is important to note that BLAZE-1, ACTIV-3 and REGN-COV2 research were
341 sponsored by the same company that designed the drug. Moreover, although all serious
342 adverse events were reported, only some were judged by investigators to be treatment related.
343 However, these studies are double-blinded. To correct the publication bias, trim-and-fill
344 method was performed and the result remained similar.

345 **ANTI-C5a**

346 At present, there was only one study investigating anti-C5a with two outcomes included in
347 this meta-analysis: the all-cause mortality and safety profile of the monoclonal antibody
348 therapy. The mortality rate in anti-C5a antibody IFX-1 (vilobelimab) group vs. placebo was
349 numerically lower, 13.3% vs 26.7%, respectively. However, this finding did not reach

350 statistical significance, probably owing to the small number of participants. Additionally,
351 compared to placebo/standard care, neither benefit nor harm was observed.

352

353 **LIMITATION**

354 This meta-analysis has several limitations: (1) some studies were open-labelled; thus, the risk
355 of bias regarding allocation concealment in those studies could not be ruled out; (2) We
356 mainly discussed IL-6R inhibitors (e.g., tocilizumab) because most published RCTs are
357 tocilizumab-associated studies and existing studies on other antibodies are scarce. (3) The
358 small number of participants in some studies may increase the likelihood of type II statistical
359 error. Larger scale RCTs are required to confirm the findings; (4) many other trials are
360 ongoing; therefore, this study needs to be updated as soon as more trials become available.
361 Nevertheless, this meta-analysis provides a solid evidence by incorporating only RCTs. To
362 the best of our knowledge, this is the first meta-analysis that investigated the efficacy and
363 safety of various monoclonal antibodies on clinical and laboratory outcomes, as well as their
364 safety profile in patients with COVID-19.

365

366 **CONCLUSION**

367 In conclusion, monoclonal antibody is beneficial in reducing mortality risk and the need for
368 mechanical ventilation, but not hospital discharge in COVID-19 patients. In contrast to
369 sarilumab, tocilizumab reduces mortality risk in severe to critical patients, reduces the need
370 for mechanical ventilation, and increases hospital discharge at day 28-30. Bamlanivimab
371 monotherapy does not reduce mortality, increase hospital discharge, nor reduce viral load;
372 while bamlanivimab-etesevimab and REGN-COV2 significantly decrease viral load. IFX-1
373 shows no benefit in mortality risk reduction. No major safety concern was documented for all
374 the monoclonal antibodies.

375

376 **Conflict of interest**

377 None declared.

378

379 **Ethical approval**

380 Not applicable.

381 **Funding**

382 None.

383

384

385 **REFERENCES**

- 386 Aziz M, Haghbin H, Abu Sitta E, Nawras Y, Fatima R, Sharma S, et al. Efficacy of
387 tocilizumab in COVID-19: A systematic review and meta-analysis. *J Med Virol*
388 2021;93(3):1620-1630, doi: 10.1002/jmv.26509.
- 389 Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk R, Furukawa T, Rochwerg B,
390 et al. Advances in the GRADE approach to rate the certainty in estimates from a network
391 meta-analysis. *J Clin Epidemiol* 2018;93:36-44, doi:10.1016/j.jclinepi.2017.10.005.
- 392 Carvelli J, Demaria O, Vély F, Batista L, Benmansour N, Fares J, et al. Association of
393 COVID-19 inflammation with activation of the C5a-C5aR1 axis. *Nature*
394 2020;588(7836):146-150, doi:10.1038/s41586-020-2600-6.
- 395 Casadevall A, Joyner MJ, Pirofski LA. Neutralizing Antibody LY-CoV555 for Outpatient
396 Covid-19. *NEJM* 2021;384(2):189, doi: 10.1056/NEJMc2033787.
- 397 Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes,
398 limitations and hopes for the future. *British Journal of Pharmacology* 2009;157(2):220-33,
399 doi: 10.1111/j.1476-5381.2009.00190.x.
- 400 Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 Neutralizing
401 Antibody LY-CoV555 in Outpatients with Covid-19. *N Engl J Med* 2021;384(3):229-237,
402 doi: 10.1056/NEJMoa2029849.
- 403 Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, et al.
404 Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic
405 hyperinflammation: an open-label cohort study. *Ann Rheum Dis* 2020;79(10):1277-1285,
406 doi: 10.1136/annrheumdis-2020-218122.
- 407 Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol A, Arabi YM, et al. Interleukin-6
408 Receptor Antagonists in Critically Ill Patients with Covid-19. *N Engl J Med*
409 2021;384(16):1491-1502, doi: 10.1056/NEJMoa2100433.
- 410 Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of Bamlanivimab as
411 Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to
412 Moderate COVID-19: A Randomized Clinical Trial. *JAMA* 2021;325(7):632-644, doi:
413 10.1001/jama.2021.0202.
- 414 Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P, et al. Effect of
415 Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe
416 Pneumonia: A Randomized Clinical Trial. *JAMA Intern Med* 2021;181(1):32-40, doi:
417 10.1001/jamainternmed.2020.6820.
- 418 Hertanto, D.M.; Sutanto, H.; Kencono Wungu, C.D. Immunomodulation as a Potent COVID-
419 19 Pharmacotherapy: Past, Present and Future. *Preprints* 2021, 2021040022, doi:
420 10.20944/preprints202104.0022.v1.
- 421 Horby PW, Pessoa-Amorim G, Peto L, Brightling CE, Sarkar R, Thomas K, et al.
422 Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary
423 results of a randomised, controlled, open-label, platform trial. *medRxiv* 2021, doi:
424 10.1101/2021.02.11.21249258.

- 425 Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nature*
426 *Reviews Microbiology* 2021;19(3):141-154, doi: 10.1038/s41579-020-00459-7.
- 427 Kotak S, Khatri M, Malik M, Malik M, Hassan W, Amjad A, et al. Use of Tocilizumab in
428 COVID-19: A Systematic Review and Meta-Analysis of Current Evidence. *Cureus*
429 2020;12(10):e10869, doi: 10.7759/cureus.10869.
- 430 Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier
431 state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome
432 coronavirus 2 (SARS-CoV-2): facts and myths. *J Microbiol Immunol Infect* 2020;53(3):404-
433 412, doi: 10.1016/j.jmii.2020.02.012.
- 434 Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-
435 19: a systematic review and meta-analysis. *Int J Antimicrob Agents* 2020;56(3):106103, doi:
436 10.1016/j.ijantimicag.2020.106103.
- 437 Leisman D, Ronner L, Pinotti R, Sinha P, Calfee C, Hirayama A, et al. Cytokine elevation in
438 severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison
439 with other inflammatory syndromes. *The Lancet Respiratory Medicine* 2020;8(12):1233-
440 1244, doi: 10.1016/S2213-2600(20)30404-5.
- 441 Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, et al. Sarilumab in patients
442 admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-
443 controlled, phase 3 trial. *Lancet Respir Med* 2021;5:522-532, doi: 10.1016/S2213-
444 2600(21)00099-0.
- 445 Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). *Nat*
446 *Rev Drug Discov* 2020;19(3):149-150, doi: 10.1038/d41573-020-00016-0.
- 447 Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in
448 Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New England Journal of*
449 *Medicine* 2020;382(13):1199-1207, doi: 10.1056/nejmoa2001316.
- 450 Lin WT, Hung SH, Lai CC, Wang CY, Chen CH. The effect of tocilizumab on COVID-19
451 patient mortality: A systematic review and meta-analysis of randomized controlled trials. *Int*
452 *Immunopharmacol* 2021;96:107602, doi: 10.1016/j.intimp.2021.107602.
- 453 Lipman N, Jackson L, Trudel L, Garcia FW. Monoclonal Versus Polyclonal Antibodies:
454 Distinguishing Characteristics, Applications, and Information Resources. *ILAR Journal*
455 2005;46(3):258-268, doi: 10.1093/ilar.46.3.258.
- 456 Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). *Biosci Trends*
457 2020;14(1):69-71, doi: 10.5582/bst.2020.01020.
- 458 Lundgren JD, Grund B, Barkauskas CE, Holland T, Gottlieb RL, Sandkovsky U, et al. A
459 Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. *N Engl J Med*
460 2021;384(10):905-914, doi: 10.1056/NEJMoa2033130.
- 461 Patel S, Saxena B, Mehta P. Recent updates in the clinical trials of therapeutic monoclonal
462 antibodies targeting cytokine storm for the management of COVID-19. *Heliyon*
463 2021;7(2):e06158, doi: 10.1016/j.heliyon.2021.e06158.

- 464 Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A
465 GRADE Working Group approach for rating the quality of treatment effect estimates from
466 network meta-analysis. *BMJ* 2014;349:g5630, doi: 10.1136/bmj.g5630.
- 467 Rosas IO, Bräu N, Waters M, Hunter BD, Bhagani S, Skiest D, et al. Tocilizumab in
468 Hospitalized Patients with Severe Covid-19 Pneumonia. *N Engl J Med* 2021;384(16):1503-
469 1516, doi: 10.1056/NEJMoa2028700.
- 470 Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients
471 Hospitalized with Covid-19 Pneumonia. *N Engl J Med* 2021;384(1):20-30, doi:
472 10.1056/NEJMoa2030340.
- 473 Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. Effect of
474 Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-
475 19 Pneumonia: A Randomized Clinical Trial. *JAMA Intern Med* 2021;181(1):24-31, doi:
476 10.1001/jamainternmed.2020.6615.
- 477 Sinha P, Calfee CS, Cherian S, Brealey D, Cutler S, King C, et al. Prevalence of phenotypes
478 of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective
479 observational study. *Lancet Respir Med* 2020;8(12):1209-1218, doi: 10.1016/S2213-
480 2600(20)30366-0.
- 481 Soin AS, Kumar K, Choudhary NS, Sharma P, Mehta Y, Kataria S, et al. Tocilizumab plus
482 standard care versus standard care in patients in India with moderate to severe COVID-19-
483 associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised,
484 controlled, phase 3 trial. *Lancet Respir Med* 2021;9(5):511-521, doi: 10.1016/S2213-
485 2600(21)00081-3.
- 486 Sterne J, Murthy S, Diaz J, Slutsky A, Villar J, Angus DC, et al. Association Between
487 Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With
488 COVID-19: A Meta-analysis. *JAMA* 2020;324(13):1330-1341, doi:
489 10.1001/jama.2020.17023.
- 490 Sterne JAC, Savović J, Page MJ, Elbers R, Blencowe N, Boutron I, et al. RoB 2: a revised
491 tool for assessing risk of bias in randomised trials. *BMJ* 2019;366: 14898, doi:
492 10.1136/bmj.l4898.
- 493 Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes A, et al. Efficacy
494 of Tocilizumab in Patients Hospitalized with Covid-19. *N Engl J Med* 2020;383(24):2333-
495 2344, doi: 10.1056/NEJMoa2028836.
- 496 Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus
497 spike protein by a SARS coronavirus-specific human monoclonal antibody. *Emerg Microbes*
498 *Infect* 2020;9(1):382-385, doi: 10.1080/22221751.2020.1729069.
- 499 Tleyjeh IM, Kashour Z, Damlaj M, Riaz M, Tlayjeh H, Altannir M, et al. Efficacy and safety
500 of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. *Clin*
501 *Microbiol Infect* 2021;27(2):215-227, doi: 10.1016/j.cmi.2020.10.036.
- 502 U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA revokes
503 emergency use authorization for monoclonal antibody bamlanivimab. News release. Food
504 and Drug Administration. 2021. [Accessed 19 April 2021] <https://www.fda.gov/news>

- 505 events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-
506 authorization-monoclonal-antibody bamlanivimab.
- 507 U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: November 9, 2020.
508 Food and Drug Administration. 2020. [Accessed 2 February 2021]
509 <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-november-9-2020>.
- 511 Vaidya K, Oleksijew A, Tucker L, Pappano W, Anderson M, Grinnell C, et al. A “Prozone-
512 Like” Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the
513 Hepatocyte Growth Factor Receptor. *Pharmacology* 2017;100(5-6):229-242, doi:
514 10.1159/000478663.
- 515 Veiga VC, Prats JAG, Farias DLC, Dourado LK, Zampieri F, Machado FR, et al. Effect of
516 tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus
517 disease 2019: randomised controlled trial. *BMJ* 2021;372:n84, doi: 10.1136/bmj.n84.
- 518 Vlaar APJ, de Bruin S, Busch M, Timmermans S, van Zeggeren I, Koning R, et al. Anti-C5a
519 antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe
520 COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.
521 *Lancet Rheumatol* 2020;12:764-773, doi: 10.1016/S2665-9913(20)30341-6.
- 522 Walls A, Park Y, Tortorici M, Wall A, McGuire A, Veesler D. Structure, Function, and
523 Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* 2020;181(2):281-292.e6, doi:
524 10.1016/j.cell.2020.02.058.
- 525 Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a
526 Neutralizing Antibody Cocktail, in Outpatients with Covid-19. *N Engl J Med*
527 2021;384(3):238-251, doi: 10.1056/NEJMoa2035002.
- 528 Woodruff T, Shukla A. The Complement C5a-C5aR1 GPCR Axis in COVID-19
529 Therapeutics. *Trends in Immunology* 2020;41(11):965-967, doi:
530 <https://doi.org/10.1016/j.it.2020.09.008>.
- 531 Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19
532 patients with tocilizumab. *Proc Natl Acad Sci U S A* 2020;117(20):10970-10975, doi:
533 10.1073/pnas.2005615117.
- 534 Yang L, Liu W, Yu X, Wu M, Reichert JM, Ho M. COVID-19 antibody therapeutics tracker:
535 a global online database of antibody therapeutics for the prevention and treatment of COVID-
536 19. *Antibody Therapeutics* 2020;3(3):205-212, doi: 10.1093/abt/tbaa020.
- 537 Zhang C, Wu Z, Li JW, Zhao H, Wang G. Cytokine release syndrome in severe COVID-19:
538 interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. *Int J
539 Antimicrob Agents* 2020;55(5):105954, doi: 10.1016/j.ijantimicag.2020.105954.
- 540 Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational Use of Tocilizumab in the Treatment of
541 Novel Coronavirus Pneumonia. *Clin Drug Investig* 2020;40(6):511-518, doi:
542 10.1007/s40261-020-00917-3.

- 543 Zhao H, Zhu Q, Zhang C, Li J, Wei M, Qin Y, et al. Tocilizumab combined with favipiravir
544 in the treatment of COVID-19: A multicenter trial in a small sample size. *Biomed*
545 *Pharmacother* 2021;133:110825, doi: 10.1016/j.biopha.2020.110825.
- 546 Zhao M, Lu J, Tang Y, Dai Y, Zhou J, Wu Y. Tocilizumab for treating COVID-19: a
547 systemic review and meta-analysis of retrospective studies. *Eur J Clin Pharmacol*
548 2021;77(3):311-319, doi: 10.1007/s00228-020-03017-5.
- 549 Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine
550 and anti-IL-6 monoclonal antibodies. *Int J Antimicrob Agents* 2020;55(6):105982, doi:
551 10.1016/j.ijantimicag.2020.105982.




Figure 1 PRISMA diagram of the literature search




Figure 2 Subgroup analysis between types of monoclonal antibody and mortality among COVID-19 patients




Figure 3 Subgroup analysis between types of monoclonal antibody and the need for mechanical ventilation among COVID-19 patients




Figure 4 Subgroup analysis between types of monoclonal antibody and the number of COVID-19 patients discharged from hospital at day 28-30




Figure 5 Forest plot for the correlation between monoclonal antibody and viral load change from baseline




Figure 6 Subgroup analysis between types of monoclonal antibody and the number of serious adverse events in COVID-19